Stock exchanges & markets

Overview Watchlists

Kuros Biosciences 9M 2026 EBITDA jumps 81% to USD 13.5 million

15. Oct 2026

(AWP Alliance News) - Kuros Biosciences' total Group EBITDA jumped 81% year over year to USD 13.5 million in the first nine months of 2026. Total Medical Device sales rose 40% to USD 141.8 million. Its new Alpharetta, Georgia, facility began commercial production of MagnetOs bone graft in October, establishing dual-site manufacturing alongside its Netherlands facility.

The group raised its full-year 2026 guidance, now expecting sales growth of 36% to 40%.

http://www.globenewswire.com/newsroom/news.html?d=1001277818

Disclaimer: This news brief was created using generative artificial intelligence. Kuros Biosciences AG published the original content used to generate this news brief via GlobeNewswire on October 15, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now